学术探索
学术期刊
新闻热点
数据分析
智能评审

Monoclonal antibody as therapy for malignant lymphomas

被引：43
作者：
Coiffier, B
机构：
[1] Hospices Civils Lyon, Serv Hematol, F-69495 Pierre Benite, France
[2] Univ Lyon 1, F-69495 Pierre Benite, France
来源：
COMPTES RENDUS BIOLOGIES | 2006年 / 329卷 / 04期
关键词：
rituximab; R-CHOP; follicular lymphoma; diffuse large B-cell lymphoma; radio-labelled antibodies; monoclonal antibodies;
D O I：
10.1016/j.crvi.2005.12.006
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Rituximab was the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies have demonstrated its activity in follicular lymphoma, mantle-cell lymphoma, and diffuse large B-cell lymphoma in untreated or relapsing patients. Because of its high activity and low toxicity ratio, rituximab has transformed the outcome of patients with B-cell lymphoma. A combination of rituximab plus chemotherapy, R-CHOP has the highest efficacy ever described with any chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma. The role of radio-labelled antibodies is still to be defined.
引用
收藏
页码：241 / 254
页数：14
相关论文
共 87 条
  • [1] Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial
    Ardeshna, KM
    Smith, P
    Norton, A
    Hancock, BW
    Hoskin, PJ
    MacLennan, KA
    Marcus, RE
    Jelliffe, A
    Hudson, GV
    Linch, DC
    [J]. LANCET, 2003, 362 (9383) : 516 - 522
  • [2] Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma:: a single institution study
    Belhadj, K
    Delfau-Larue, MH
    Elgnaoui, T
    Beaujean, F
    Beaumont, JL
    Pautas, C
    Gaillard, I
    Kirova, Y
    Allain, A
    Gaulard, P
    Farcet, JP
    Reyes, F
    Haioun, C
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (03) : 504 - 510
  • [3] Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
    Berinstein, NL
    Grillo-Lopez, AJ
    White, CA
    Bence-Bruckler, I
    Maloney, D
    Czuczman, M
    Green, D
    Rosenberg, J
    McLaughlin, P
    Shen, D
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (09) : 995 - 1001
  • [4] Bienvenu J, 2001, Hematol J, V2, P378, DOI 10.1038/sj.thj.6200133
  • [5] Evidence for Fcγ receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy.
    Boettcher, S
    Pott, C
    Ritgen, M
    Hiddemann, W
    Unterhalt, M
    Kneba, M
    [J]. BLOOD, 2004, 104 (11) : 170A - 171A
  • [6] Variation in gene expression patterns in follicular lymphoma and the response to rituximab
    Bohen, SP
    Troyanskaya, OG
    Alter, O
    Warnke, R
    Botstein, D
    Brown, PO
    Levy, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) : 1926 - 1930
  • [7] Clearing minimal residual disease with rituximab consolidation therapy
    Brugger, W
    [J]. SEMINARS IN ONCOLOGY, 2004, 31 (01) : 33 - 37
  • [8] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    Byrd, JC
    Peterson, BL
    Morrison, VA
    Park, K
    Jacobson, R
    Hoke, E
    Vardiman, JW
    Rai, K
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 2003, 101 (01) : 6 - 14
  • [9] Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    Byrd, JC
    Rai, K
    Peterson, BL
    Appelbaum, FR
    Morrison, VA
    Kolitz, JE
    Shepherd, L
    Hines, JD
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 2005, 105 (01) : 49 - 53
  • [10] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
    Byrd, JC
    Murphy, T
    Howard, RS
    Lucas, MS
    Goodrich, A
    Park, K
    Pearson, M
    Waselenko, JK
    Ling, G
    Grever, MR
    Grillo-Lopez, AJ
    Rosenberg, J
    Kunkel, L
    Flinn, IW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2153 - 2164
123456789